U.S. government advisers met Wednesday to decide whether to endorse COVID-19 shots for babies, toddlers and preschoolers, moving the nation closer to vaccinations for all ages.
Kids under 5 are the last remaining age group in the U.S. to get vaccinated and many parents have been anxiously awaiting Food and Drug Administration action to protect their little children. If all the regulatory hurdles are cleared, shots should be available next week.
Dr. Peter Marks, FDA’s vaccine chief, opened the meeting with data showing a “quite troubling surge’’ in young children’s hospitalizations during the omicron wave, and noted 442 children under 4 have died during the pandemic. That’s far fewer than adult deaths, but should not be dismissed in considering the need for vaccinating the youngest kids, he said.
“Each child that’s lost essentially fractures a family,’’ Marks said.
FDA reviewers said both brands appear to be safe and effective for children as young as 6 months old in analyses posted ahead of the all-day meeting. Side effects, including fever and fatigue, were generally minor in both, and less common than seen in adults.
The two vaccines use the same technology but there are differences. In a call with reporters earlier this week, vaccine experts noted that the shots haven’t been tested against each other, so there’s no way to tell parents if one is superior.
“That is a really important point,”’ said Dr. Jesse Goodman of Georgetown University, a former FDA vaccine chief. “You can’t compare the vaccines directly.’’
If the FDA clears the shots, there’s one more step. The Centers for Disease Control and Prevention will decide on a formal recommendation after its own advisers meet Saturday. If the CDC signs off, shots could be available as soon as Monday or Tuesday at doctor’s offices, hospitals and pharmacies. Roughly 18 million youngsters would be eligible.
Moderna’s shots are one-quarter the dose of the company’s adult shots. Two doses appeared strong enough to prevent severe infections but only about 40% to 50% effective at preventing milder infections. Moderna has added a booster to its study.
“I think all of us agree these children will need a third dose at some point in time,” Moderna’s Dr. Jacqueline Miller told the panel.
Pfizer’s submitted data found no safety concerns and suggested that three shots were 80% effective in preventing symptomatic coronavirus infections. But that was based on just 10 COVID-19 cases; the calculation could change as more cases occur in the company’s ongoing studies.
The same FDA panel on Tuesday backed Moderna‘s half-sized shots for ages 6 to 11 and full-sized doses for teens. If authorized by the FDA, it would be the second option for those age groups. Currently Pfizer vaccine is their only choice.
The nation’s vaccination campaign started in December 2020 with the rollout of adult vaccines from Pfizer and Moderna, with health care workers and nursing home residents first in line. Teens and school-age children were added last year.
Moderna said in April that it is also seeking regulatory approval outside the U.S. for its little kid shots. According to the World Health Organization, 12 other countries already vaccinate kids under 5, with other brands.
In the U.S., it remains uncertain how many parents want their youngest vaccinated. While COVID-19 is generally less dangerous for young children than older kids and adults, there have been serious cases and some deaths. Many parents trying to keep unvaccinated tots safe have put off family trips or enrolling children in daycare or preschool.
Still, by some estimates, three-quarters of all children have already been infected. Only about 29% of children aged 5 to 11 have been vaccinated since Pfizer’s shots opened to them last November, a rate far lower than public health authorities consider ideal.
Dr. Nimmi Rajagopal, a family medicine physician at Cook County Health in Chicago, said she’s been preparing parents for months.
“We have some that are hesitant, and some that are just raring to go,’’ she said.
Copyright © 2022 The Washington Times, LLC.